4.7 Review

Cardiovascular Diseases of Developmental Origins: Preventive Aspects of Gut Microbiota-Targeted Therapy

期刊

NUTRIENTS
卷 13, 期 7, 页码 -

出版社

MDPI
DOI: 10.3390/nu13072290

关键词

aryl hydrocarbon receptor; cardiovascular disease; hypertension; gut microbiota; postbiotics; short chain fatty acid; prebiotics; probiotics; trimethylamine-N-oxide; developmental origins of health and disease (DOHaD)

资金

  1. Chang Gung Memorial Hospital, Kaohsiung, Taiwan [CMRPG8J0253, CORPG8J0121, CORPG8L0121, CORPG8L0261, CORPG8L0301]

向作者/读者索取更多资源

Research has shown a link between early gut microbiota and cardiovascular diseases, leading to targeted therapies such as probiotics, prebiotics, and postbiotics. Reprogramming interventions targeting the gut microbiota have shown promise in preventing cardiovascular diseases. Further studies will be needed to fully implement these findings into practice.
Cardiovascular diseases (CVDs) can originate from early life. Accumulating evidence suggests that gut microbiota in early life is linked to CVDs in later life. Gut microbiota-targeted therapy has gained significant importance in recent decades for its health-promoting role in the prevention (rather than just treatment) of CVDs. Thus far, available gut microbiota-based treatment modalities used as reprogramming interventions include probiotics, prebiotics, and postbiotics. The purpose of this review is, first, to highlight current studies that link dysbiotic gut microbiota to the developmental origins of CVD. This is followed by a summary of the connections between the gut microbiota and CVD behind cardiovascular programming, such as short chain fatty acids (SCFAs) and their receptors, trimethylamine-N-oxide (TMAO), uremic toxins, and aryl hydrocarbon receptor (AhR), and the renin-angiotensin system (RAS). This review also presents an overview of how gut microbiota-targeted reprogramming interventions can prevent the developmental origins of CVD from animal studies. Overall, this review reveals that recent advances in gut microbiota-targeted therapy might provide the answers to reduce the global burden of CVDs. Still, additional studies will be needed to put research findings into practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据